Unknown

Dataset Information

0

Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

ABSTRACT: The cyclin-dependent kinase 5 (CDK5), originally described as a neuronal-specific kinase, is also frequently activated in human cancers. Using conditional CDK5 knockout mice and a mouse model of highly metastatic melanoma, we found that CDK5 is dispensable for the growth of primary tumors. However, we observed that ablation of CDK5 completely abrogated the metastasis, revealing that CDK5 is essential for the metastatic spread. In mouse and human melanoma cells CDK5 promotes cell invasiveness by directly phosphorylating an intermediate filament protein, vimentin, thereby inhibiting assembly of vimentin filaments. Chemical inhibition of CDK5 blocks the metastatic spread of patient-derived melanomas in patient-derived xenograft (PDX) mouse models. Hence, inhibition of CDK5 might represent a very potent therapeutic strategy to impede the metastatic dissemination of malignant cells.

SUBMITTER: Sharma S 

PROVIDER: S-EPMC7149478 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The cyclin-dependent kinase 5 (CDK5), originally described as a neuronal-specific kinase, is also frequently activated in human cancers. Using conditional CDK5 knockout mice and a mouse model of highly metastatic melanoma, we found that CDK5 is dispensable for the growth of primary tumors. However, we observed that ablation of CDK5 completely abrogated the metastasis, revealing that CDK5 is essential for the metastatic spread. In mouse and human melanoma cells CDK5 promotes cell invasiveness by  ...[more]

Similar Datasets

Unknown Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
| S-EPMC8568331 | biostudies-literature
Unknown Targeting cyclin-dependent kinase 9 in cancer therapy.
| S-EPMC9253122 | biostudies-literature
Unknown Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.
| S-EPMC5834273 | biostudies-literature
Unknown The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
| S-EPMC3601112 | biostudies-literature
Unknown Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.
| S-EPMC4090515 | biostudies-literature
Unknown Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
| S-EPMC3490842 | biostudies-literature
Unknown MicroRNA-337-3p impedes breast cancer progression by targeting cyclin-dependent kinase 1.
| S-EPMC8607341 | biostudies-literature
Unknown Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
| S-EPMC5364079 | biostudies-literature
Unknown Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
| S-EPMC3100964 | biostudies-literature
Unknown Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
| S-EPMC7595101 | biostudies-literature